For how we live.
A 23 October label change adds a 720 mg subcutaneous starting course at weeks 0, 2, 4 and 8, letting patients begin risankizumab without the three intravenous infusions the drug has required since 2022.
At one year, 79% of newly diagnosed patients given early infliximab plus an immunomodulator were in steroid-free, surgery-free remission, versus 15% treated conventionally.
In 53 patients, oral fluconazole — but not a mouth-only antifungal — cut gut Candida and coincided with improved disease activity. The study was observational, brief and unblinded.
The FDA's approval bar requires no clinically meaningful difference from the original, and a large switching trial found no loss of control. The savings gap is a market problem, not a safety one.
REMEASURE randomised 73 patients to Kono-S anastomosis or mesenteric resection after ileocolic surgery for Crohn's disease; endoscopic recurrence at six months was 33% versus 32%.
In the open-label extension of the VIVID programme, remission rates stayed high at 104 weeks — but no placebo group ran alongside, so durability is described, not proven, against nature.